Hypomania after augmenting venlafaxine and olanzapine with sarcosine in a patient with schizophrenia: a case study

Código QR

Hypomania after augmenting venlafaxine and olanzapine with sarcosine in a patient with schizophrenia: a case study

Dominik Strzelecki, Justyna Szyburska, Magdalena Kotlicka-Antczak, Olga KałużyńskaDepartment of Affective and Psychotic Disorders, Medical University of Lódz, Central Clinical Hospital, Lódz, PolandAbstract: Glutamate is the main excitatory neurotransmitter in the central nerv...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Strzelecki D, Szyburska J, Kotlicka-Antczak M, Kałużyńska O
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2015
Materias:	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/2b6139f2702e437c8f373a2e5e523b37
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Odor perception and hedonics in chronic schizophrenia and in first episode psychosis
por: Urban-Kowalczyk M, et al.
Publicado: (2019)

The Relationship Between Antipsychotic Treatment and Plasma β-Endorphin Concentration in Patients with Schizophrenia
por: Urban-Kowalczyk M, et al.
Publicado: (2021)

The Relationship Between Course of Illness and β-Endorphin Plasma Levels in Patients with Schizophrenia
por: Urban-Kowalczyk M, et al.
Publicado: (2020)

Antidepressant therapy with milnacipran and venlafaxine
por: Lucilla Mansuy
Publicado: (2010)

Profile of olanzapine long-acting injection for the maintenance treatment of adult patients with schizophrenia
por: Rosaria Di Lorenzo, et al.
Publicado: (2010)

Telomere length in blood cells is related to the chronicity, severity, and recurrence rate of schizophrenia
por: Pawelczyk T, et al.
Publicado: (2015)

Efficacy of ginkgo biloba extract as augmentation of venlafaxine in treating post-stroke depression
por: Liang ZH, et al.
Publicado: (2019)

Gabapentin adjunctive to risperidone or olanzapine in partially responsive schizophrenia: an open-label pilot study
por: Adel Gabriel
Publicado: (2010)

A naturalistic comparison of the efficacy and safety of intramuscular olanzapine and intramuscular levomepromazine in agitated elderly patients with schizophrenia
por: Suzuki H, et al.
Publicado: (2013)

Reduced serum paraoxonase 1 (PON1) activity in patients with schizophrenia treated with olanzapine but not quetiapine
por: &Uuml;nsal C, et al.
Publicado: (2013)

Antipsychotic monotherapy among outpatients with schizophrenia treated with olanzapine or risperidone in Japan: a health care database analysis
por: Takahashi M, et al.
Publicado: (2012)

Comparison of somnolence associated with asenapine, olanzapine, risperidone, and haloperidol relative to placebo in patients with schizophrenia or bipolar disorder
por: Gao K, et al.
Publicado: (2013)

Long-term functional improvements in the 2-year treatment of schizophrenia outpatients with olanzapine long-acting injection
por: Ascher-Svanum H, et al.
Publicado: (2014)

Augmentation with antidepressants in schizophrenia treatment: benefit or risk
por: Mao YM, et al.
Publicado: (2015)

Influence of olanzapine on serum prolactin levels and BMI in female patients with schizophrenia
por: Yang F, et al.
Publicado: (2018)

Olanzapine approved for the acute treatment of schizophrenia or manic/mixed episodes associated with bipolar I disorder in adolescent patients
por: Ann E Maloney, et al.
Publicado: (2010)

A commentary on the efficacy of olanzapine for the treatment of schizophrenia: the past, present, and future
por: Citrome L, et al.
Publicado: (2019)

Does participation in a weight control program also improve clinical and functional outcomes for Chinese patients with schizophrenia treated with olanzapine?
por: Montgomery W, et al.
Publicado: (2014)

An economic evaluation of aripiprazole vs olanzapine adapted to the Italian setting using outcomes of metabolic syndrome and risk for diabetes in patients with schizophrenia
por: Giorgio L Colombo, et al.
Publicado: (2008)

Effects of switching from olanzapine to aripiprazole on the metabolic profiles of patients with schizophrenia and metabolic syndrome: a double-blind, randomized, open-label study
por: Wani RA, et al.
Publicado: (2015)

Effects of switching from olanzapine to aripiprazole on the metabolic profiles of patients with schizophrenia and metabolic syndrome: a double-blind, randomized, open-label study [Corrigendum]
por: Wani RA, et al.
Publicado: (2015)

Effectiveness and safety of oral olanzapine treatment transitioned from rapid-acting intramuscular olanzapine for agitation associated with schizophrenia
por: Katagiri H, et al.
Publicado: (2018)

Switching to olanzapine long-acting injection from either oral olanzapine or any other antipsychotic: comparative post hoc analyses
por: Ciudad A, et al.
Publicado: (2013)

Reversal of olanzapine-induced weight gain in a patient with schizophrenia by switching to asenapine: a case report
por: Okazaki K, et al.
Publicado: (2017)

Olanzapine–valproate combination versus olanzapine or valproate monotherapy in the treatment of bipolar I mania: a randomized controlled study in a Chinese population group
por: Xu L, et al.
Publicado: (2015)

Long-acting injectable antipsychotics: focus on olanzapine pamoate
por: JP Lindenmayer
Publicado: (2010)

Comparison of patients undergoing switching versus augmentation of antipsychotic medications during treatment for schizophrenia
por: Ascher-Svanum H, et al.
Publicado: (2012)

A 6-year open-label study of the efficacy and safety of olanzapine long-acting injection in patients with schizophrenia: a post hoc analysis based on the European label recommendation
por: An, et al.
Publicado: (2015)

The effectiveness and safety of amisulpride in Chinese patients with schizophrenia who switch from risperidone or olanzapine: a subgroup analysis of the ESCAPE study
por: Liang Y, et al.
Publicado: (2017)

Risperidone, quetiapine, and olanzapine adjunctive treatments in major depression with psychotic features: a comparative study
por: Gabriel A
Publicado: (2013)

Comparison of beta-endorphin and CGRP levels before and after treatment for severe schizophrenia
por: Urban-Kowalczyk M, et al.
Publicado: (2016)

Erratum:&nbsp;An economic evaluation of aripiprazole vs olanzapine adapted to the Italian setting using outcomes of metabolic syndrome and risk for diabetes in patients with schizophrenia. Neuropsychiatr Dis Treat, 4: 967&ndash;976
por: Colombo GL, et al.
Publicado: (2009)

Effects of risperidone and olanzapine on remnant-like lipoprotein particle cholesterol (RLP-C) in schizophrenic patients
por: Takahiko Nagamine
Publicado: (2008)

Olanzapine and fluoxetine combination therapy for treatment-resistant depression: review of efficacy, safety, and study design issues
por: William&nbsp;V Bobo, et al.
Publicado: (2009)

Obsessive-compulsive disorder with bipolar diathesis following isotretinoin therapy remitting upon treatment with olanzapine and fluvoxamine
por: Michele Fornaro
Publicado: (2010)

Milnacipran and venlafaxine at flexible doses (up to 200 mg/day) in the outpatient treatment of adults with moderate-to-severe major depressive disorder: a 24-week randomized, double-blind exploratory study
por: Jean-Pierre Oli&eacute;, et al.
Publicado: (2010)

Correlation between changes in quality of life and symptomatic improvement in Chinese patients switched from typical antipsychotics to olanzapine
por: Montgomery W, et al.
Publicado: (2015)

Dosage-related nature of escitalopram treatment-emergent mania/hypomania: a case series
por: Yamaguchi Y, et al.
Publicado: (2018)

Safety and effectiveness of rapid-acting intramuscular olanzapine for agitation associated with schizophrenia – Japan postmarketing surveillance study
por: Katagiri H, et al.
Publicado: (2018)

Correction to: Association between hyperpyrexia and poststroke outcomes in patients with recanalization after mechanical thrombectomy: a retrospective cohort study
por: Man Chen, et al.
Publicado: (2021)